logo

MDT

Medtronic·NYSE
--
--(--)
--
--(--)
9.56 / 10
Outperform

Medtronic's fundamentals are outstanding, scoring 9.6/10. Key strengths include a healthy asset-to-market value (0.2285, Group 3), solid net income relative to revenue (0.2601, Group 2), and an impressive return on assets (5.1646, Group 4). Cash metrics are improving (Cash-MV 0.3047, Group 3), and profitability remains high (Net profit / Total profit 83.35%, Group 1). Interest coverage (8.72) and profit attribution (99.38%) further reinforce financial resilience. The primary concern is revenue-to-market value (0.0360, Group 2), which has shown negative historical returns, suggesting slower top-line growth ahead.

Fundamental(9.56)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value0.04
Score0/3
Weight-64.08%
1M Return-3.84%
ROA (%)
Value5.16
Score3/3
Weight20.88%
1M Return1.03%
Net profit attributable to parent company shareholders / Net profit (%)
Value99.38
Score2/3
Weight-29.36%
1M Return-1.71%
Net income-Revenue
Value0.26
Score2/3
Weight58.93%
1M Return2.59%
Cash-UP
Value-0.03
Score2/3
Weight-71.58%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value5.16
Score3/3
Weight20.88%
1M Return1.03%
Interest coverage ratio (EBIT / Interest expense) (%)
Value8.72
Score2/3
Weight-33.10%
1M Return-1.95%
Asset-MV
Value0.23
Score2/3
Weight34.44%
1M Return1.60%
Cash-MV
Value0.30
Score3/3
Weight138.41%
1M Return5.98%
Net profit / Total profit (%)
Value83.35
Score3/3
Weight24.58%
1M Return1.20%
Is MDT fundamentally strong?
  • MDT scores 9.56/10 on fundamentals and holds a Discounted valuation at present. Backed by its 4.97% ROE, 13.79% net margin, 27.70 P/E ratio, 2.70 P/B ratio, and 13.41% earnings growth, these metrics solidify its Outperform investment rating.